Navigation Links
Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication
Date:9/23/2011

CHAPEL HILL, N.C., Sept. 23, 2011 /PRNewswire/ -- A pharmaceutical company's marketing strategy must undergo many critical changes to avoid cannibalization when introducing a new brand in a space where the company already has an established brand. For more than two-thirds of companies, the most frequent changes require shifting resources and funds to support the new product through activities, such as professional relations, promotional literature, sampling, and advisory boards/thought leader development.

However, spending priorities for the legacy product must shift as well. On average, sampling, coupon-discount programs and direct mail become more important, while ad boards, class-building activities and speaker training become less important for the legacy brand's continued success, according to "Expanding a Product Portfolio without Cannibalizing an Established Brand," primary research conducted by Best Practices, LLC.

Download a complimentary white paper at http://www3.best-in-class.com/rr1120.htm that includes selected best practices drawn from extensive primary research with brand leaders from 22 different pharmaceutical, biotechnology and medical device companies.

"Expanding a Product Portfolio without Cannibalizing an Established Brand" is a 61-page report with more than 130 benchmark metrics and 37 executive narratives, providing marketing and brand executives with valuable insights and exhaustive data to plan and implement marketing strategies for multiple, high-performing brands in the same indication.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.  

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
4. Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets
5. Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
9. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
10. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
11. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... ... in Atlanta, opened their doors. They celebrate 30 years in business this year, ... create an up-to-date, inviting, tranquil space to serve their patients. , It ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 2017 , ... A global leader in the treatment of clubfoot, CURE ... Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong disability ... on track to enroll 10,000 children in the clubfoot treatment program in this year ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced their ... a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content will ... in 2018. Proceeds will be going to further health research. , Fusion Flix ...
Breaking Medicine News(10 mins):